Business Of Biotech
Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.
Feb 12, 2024
On this episode, Mark Kotter, CEO of Bit.bio, discusses the concept of programmable biology and the challenges involved in building capabilities. They delve into the interdisciplinary team required, the innovative cell reprogramming at Bit.bio, focusing on regenerative medicine indications, funding journey, stem cell reprogramming for aging interventions, and visibility in the biotech space.
45:51
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- BitBio exemplifies programmable biology in biotech by assembling a diverse team for cell therapy development.
- Dr. Mark Cotter transitioned from academia to biotech entrepreneurship by creating a multidisciplinary team for cell therapy challenges.
Deep dives
The Concept of Programmable Biology in Biotech
BitBio is a preclinical cell therapy company that exemplifies the new breed of biotech fueled by programmable biology. The company is developing therapeutics in various areas, such as metabolism, endocrinology, immunology, and neurology. To build its capabilities, BitBio has assembled a diverse team of stem cell biologists, synthetic biologists, genetic engineering experts, sequencing experts, data scientists, and more. The focus is on creating a platform that can reproduce any human cell type using transcription factor programming. This approach allows for consistency, scalability, and functionality of the cells, with the goal of democratizing access to therapies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
